Snuunary We have conducted a retrospective study of high-dose folimc acid and 5-fluorouracil in % patients with advanced colorectal cancer. Patients received 200mg m -(maximum 300-350 mg) folinic acid by infusion over 2 h followed by an i.v. bolus of 5-fluorouracil 400mg m -then an infusion of 5-fluorouracil 600 mg m -' over 22 h. This was repeated over the next 24 h. The schedule was given every 2 weeks for four cycles; thereafter patients with objective response continued to a maximum of eight cycles. The overall response rate was 10.6% in 85 evaluable patients. The median duration of response was 11 months. The median survival was 6 months. Toxicity was low, only one patient experiencing toxicity greater than WHO grade II (grade IV platelet toxicity). Diarrhoea, nausea, vomiting and mucositis also occurred but were mild and infrequent. Our low response rate may be related to factors such as patient characteristics or duration of treatment.
5-Fluorouracil (5-FU) is the commonest chemotherapeutic agent used in the treatment of advanced colorectal cancer. The response rate to single-agent 5-FU in bolus form is only 11% (Advanced Colorectal Meta-Analysis Report, 1992) , but this can be improved when 5-FU is given in combination with folinic acid (Poon et al., 1991) , albeit at the expense of increased toxicity.
In 1988 de Gramont et al. described a regimen containing high-dose folinic acid with 5-FU bolus and continuous infusion in a 2 day, 2 weekly regimen. In patients with advanced colorectal cancer, there was a high response rate (54.1%) with low toxicity. Later, Johnson et al. (1991) used the same regimen against a variety of advanced gastrointestinal malignancies, mainly colorectal. Again it was well tolerated although the response rate was lower (26%). A third study comparing this regimen with interferon reported a response rate of 30% in both arms (Seymour et al., 1994 Seventy-six patients have died. The median follow-up time for survivors was 11 months (range 3-27 months). The median survival was 6 months. Twenty-seven per cent were alive at 12 months. The survival curve is represented in Figure 1 . The median survival of the 11 unassessable patients was similar. 8 months. indicating these were not a selected group of patients. The median survival of patients achieving a partial response was 23 months.
Toxicitn'
All 96 patients were included in the toxicitv analvsis. In total. 376 cycles of chemotherapy were administered. The regimen was verv well tolerated. Only one patient had toxicity greater than WHO grade II. This patient had received previous chemotherapy and radiotherapy and suffered grade IV platelet toxicity after the first cycle. All other side-effects were WHO grade I or II. Toxicity resulted in delay of only 4 of 376 cycles of chemotherapy. There were no dose reductions. Nausea or vomniting was seen after 26 cycles (6.9%): and diarrhoea after 12 cycles (3.2%). Mucositis occurred after 11 cycles (2.900). Platelet toxicity occurred after four cycles (1.1%). There were no febrile neutropenic episodes.
Discussion
Initial reports of a sirmilar regimen were encouraging in terms of both response rate and toxicity (de Gramont et al.. 1988 : Johnson et al.. 1991 : Seymour et al.. 1994 . However a recent retrospective analysis (Jodrell et al.. 1994) reported a response rate of only 1100 although the low toxicitv was confirmed. Our centre had used the chemotherapy regimen frequently since 1991 and our study was to investigate how our response rate and toxicity compared with previous reports. In common w-ith others. we found the regimen very stopped if patients had not achieved a partial response after 2 months and the response rate was lou-er ( 110°o). In our study patients received a median of four cycles (2 months).
and we too found a low response rate. In our centre treatment was discontinued if there was no objective response to spare patients the necessity of 48 h of treatment every 2 weeks. However. the lesser amount of chemotherapy given to our patients may have resulted in a lower response rate.
Continuing treatment for longer in patients with stable disease may have allow ed more patients to achieve a response. Jodrell et al. (1994) commented that patients receiving higher doses of 5-FU were more likely to respond. However.
the total dose of 5-FU in their highest dose cohort was the same as the total dose of 5-FU in our regimen. Therefore. differences in dose within the range studied could not account solely for the poor response rate.
In conclusion. our results confirm that this chemotherapy regimen is well tolerated. and in those patients who respond a response duration similar to other studies is achieved. However. the response rate is low. Our patients were treated for a relatively short time and might have benefited had the treatment duration been longer. In addition. some of our patients were undoubtedly already deteriorating rapidly because of their disease and did not benefit from chemotherapy. Despite the low response rate, some non-responders did have a symptomatic improvement following chemotherapy. We believe the regimen needs further formal evaluation. including quality of life assessment.
